nodes	percent_of_prediction	percent_of_DWPC	metapath
Vidarabine—ADORA2A—Aminophylline—chronic obstructive pulmonary disease	0.683	1	CbGbCtD
Vidarabine—ADA—pleura—chronic obstructive pulmonary disease	0.0554	0.579	CbGeAlD
Vidarabine—ADA—respiratory system—chronic obstructive pulmonary disease	0.00551	0.0575	CbGeAlD
Vidarabine—ADA—connective tissue—chronic obstructive pulmonary disease	0.00485	0.0506	CbGeAlD
Vidarabine—DPP4—respiratory system—chronic obstructive pulmonary disease	0.00436	0.0455	CbGeAlD
Vidarabine—DPP4—connective tissue—chronic obstructive pulmonary disease	0.00384	0.0401	CbGeAlD
Vidarabine—ADK—bronchus—chronic obstructive pulmonary disease	0.0037	0.0387	CbGeAlD
Vidarabine—ADK—smooth muscle tissue—chronic obstructive pulmonary disease	0.00362	0.0378	CbGeAlD
Vidarabine—DPP4—smooth muscle tissue—chronic obstructive pulmonary disease	0.00351	0.0367	CbGeAlD
Vidarabine—ADK—trachea—chronic obstructive pulmonary disease	0.00333	0.0347	CbGeAlD
Vidarabine—ADA—lung—chronic obstructive pulmonary disease	0.00292	0.0305	CbGeAlD
Vidarabine—ADK—lung—chronic obstructive pulmonary disease	0.00239	0.0249	CbGeAlD
Vidarabine—DPP4—lung—chronic obstructive pulmonary disease	0.00232	0.0242	CbGeAlD
Vidarabine—ADA—C-MYB transcription factor network—ELANE—chronic obstructive pulmonary disease	0.0021	0.0859	CbGpPWpGaD
Vidarabine—Glucosamine—MMP9—chronic obstructive pulmonary disease	0.00202	0.491	CrCbGaD
Vidarabine—DPP4—Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)—LEP—chronic obstructive pulmonary disease	0.00164	0.0671	CbGpPWpGaD
Vidarabine—DPP4—Incretin synthesis, secretion, and inactivation—LEP—chronic obstructive pulmonary disease	0.00146	0.0597	CbGpPWpGaD
Vidarabine—Glucosamine—TNF—chronic obstructive pulmonary disease	0.00133	0.323	CrCbGaD
Vidarabine—ADORA2A—HIF-2-alpha transcription factor network—MMP14—chronic obstructive pulmonary disease	0.00108	0.0443	CbGpPWpGaD
Vidarabine—ADORA2A—Monoamine Transport—SLC6A4—chronic obstructive pulmonary disease	0.00091	0.0372	CbGpPWpGaD
Vidarabine—ADA—p73 transcription factor network—SERPINA1—chronic obstructive pulmonary disease	0.000904	0.0369	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—MPO—chronic obstructive pulmonary disease	0.000811	0.0331	CbGpPWpGaD
Vidarabine—DPP4—Peptide hormone metabolism—ACE—chronic obstructive pulmonary disease	0.000798	0.0326	CbGpPWpGaD
Vidarabine—Tension—Aminophylline—chronic obstructive pulmonary disease	0.000764	0.00398	CcSEcCtD
Vidarabine—Tenofovir—CYP1A2—chronic obstructive pulmonary disease	0.000764	0.186	CrCbGaD
Vidarabine—Mediastinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.00076	0.00396	CcSEcCtD
Vidarabine—Urticaria—Roflumilast—chronic obstructive pulmonary disease	0.000757	0.00394	CcSEcCtD
Vidarabine—Nervousness—Aminophylline—chronic obstructive pulmonary disease	0.000756	0.00394	CcSEcCtD
Vidarabine—Arrhythmia—Tiotropium—chronic obstructive pulmonary disease	0.000754	0.00392	CcSEcCtD
Vidarabine—Acute coronary syndrome—Formoterol—chronic obstructive pulmonary disease	0.000748	0.00389	CcSEcCtD
Vidarabine—Acute coronary syndrome—Arformoterol—chronic obstructive pulmonary disease	0.000748	0.00389	CcSEcCtD
Vidarabine—Myocardial infarction—Arformoterol—chronic obstructive pulmonary disease	0.000743	0.00387	CcSEcCtD
Vidarabine—Myocardial infarction—Formoterol—chronic obstructive pulmonary disease	0.000743	0.00387	CcSEcCtD
Vidarabine—Drowsiness—Montelukast—chronic obstructive pulmonary disease	0.000743	0.00387	CcSEcCtD
Vidarabine—Tremor—Aminophylline—chronic obstructive pulmonary disease	0.00073	0.0038	CcSEcCtD
Vidarabine—Drowsiness—Salbutamol—chronic obstructive pulmonary disease	0.000716	0.00373	CcSEcCtD
Vidarabine—Agitation—Aminophylline—chronic obstructive pulmonary disease	0.000716	0.00372	CcSEcCtD
Vidarabine—Back pain—Tiotropium—chronic obstructive pulmonary disease	0.00071	0.0037	CcSEcCtD
Vidarabine—Hypersensitivity—Roflumilast—chronic obstructive pulmonary disease	0.000702	0.00365	CcSEcCtD
Vidarabine—Vision blurred—Tiotropium—chronic obstructive pulmonary disease	0.000692	0.0036	CcSEcCtD
Vidarabine—Palpitations—Aminophylline—chronic obstructive pulmonary disease	0.000688	0.00358	CcSEcCtD
Vidarabine—Sweating—Salbutamol—chronic obstructive pulmonary disease	0.000687	0.00357	CcSEcCtD
Vidarabine—Asthenia—Roflumilast—chronic obstructive pulmonary disease	0.000684	0.00356	CcSEcCtD
Vidarabine—Convulsion—Aminophylline—chronic obstructive pulmonary disease	0.000675	0.00351	CcSEcCtD
Vidarabine—Angioedema—Tiotropium—chronic obstructive pulmonary disease	0.000671	0.00349	CcSEcCtD
Vidarabine—Hypoaesthesia—Montelukast—chronic obstructive pulmonary disease	0.000664	0.00345	CcSEcCtD
Vidarabine—Anxiety—Aminophylline—chronic obstructive pulmonary disease	0.000661	0.00344	CcSEcCtD
Vidarabine—Syncope—Tiotropium—chronic obstructive pulmonary disease	0.000659	0.00343	CcSEcCtD
Vidarabine—Palpitations—Tiotropium—chronic obstructive pulmonary disease	0.000649	0.00338	CcSEcCtD
Vidarabine—Loss of consciousness—Tiotropium—chronic obstructive pulmonary disease	0.000646	0.00336	CcSEcCtD
Vidarabine—Cough—Tiotropium—chronic obstructive pulmonary disease	0.000641	0.00334	CcSEcCtD
Vidarabine—Hypoaesthesia—Salbutamol—chronic obstructive pulmonary disease	0.00064	0.00333	CcSEcCtD
Vidarabine—Anaphylactic shock—Aminophylline—chronic obstructive pulmonary disease	0.000636	0.00331	CcSEcCtD
Vidarabine—Hypertension—Tiotropium—chronic obstructive pulmonary disease	0.000634	0.0033	CcSEcCtD
Vidarabine—Cardiac disorder—Formoterol—chronic obstructive pulmonary disease	0.000632	0.00329	CcSEcCtD
Vidarabine—Cardiac disorder—Arformoterol—chronic obstructive pulmonary disease	0.000632	0.00329	CcSEcCtD
Vidarabine—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.00063	0.00328	CcSEcCtD
Vidarabine—Shock—Aminophylline—chronic obstructive pulmonary disease	0.000625	0.00325	CcSEcCtD
Vidarabine—Chest pain—Tiotropium—chronic obstructive pulmonary disease	0.000625	0.00325	CcSEcCtD
Vidarabine—Tachycardia—Aminophylline—chronic obstructive pulmonary disease	0.00062	0.00323	CcSEcCtD
Vidarabine—Cardiac disorder—Montelukast—chronic obstructive pulmonary disease	0.000619	0.00322	CcSEcCtD
Vidarabine—Mediastinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000614	0.00319	CcSEcCtD
Vidarabine—Mediastinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000614	0.00319	CcSEcCtD
Vidarabine—Dry mouth—Tiotropium—chronic obstructive pulmonary disease	0.000612	0.00318	CcSEcCtD
Vidarabine—Arrhythmia—Formoterol—chronic obstructive pulmonary disease	0.000608	0.00317	CcSEcCtD
Vidarabine—Arrhythmia—Arformoterol—chronic obstructive pulmonary disease	0.000608	0.00317	CcSEcCtD
Vidarabine—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.000606	0.00315	CcSEcCtD
Vidarabine—Mediastinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000601	0.00313	CcSEcCtD
Vidarabine—Rash—Roflumilast—chronic obstructive pulmonary disease	0.000601	0.00313	CcSEcCtD
Vidarabine—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.0006	0.00312	CcSEcCtD
Vidarabine—Tinnitus—Salbutamol—chronic obstructive pulmonary disease	0.000599	0.00312	CcSEcCtD
Vidarabine—Headache—Roflumilast—chronic obstructive pulmonary disease	0.000597	0.00311	CcSEcCtD
Vidarabine—Flushing—Salbutamol—chronic obstructive pulmonary disease	0.000597	0.00311	CcSEcCtD
Vidarabine—Cardiac disorder—Salbutamol—chronic obstructive pulmonary disease	0.000597	0.00311	CcSEcCtD
Vidarabine—Hypotension—Aminophylline—chronic obstructive pulmonary disease	0.000594	0.00309	CcSEcCtD
Vidarabine—Shock—Tiotropium—chronic obstructive pulmonary disease	0.00059	0.00307	CcSEcCtD
Vidarabine—Tachycardia—Tiotropium—chronic obstructive pulmonary disease	0.000585	0.00304	CcSEcCtD
Vidarabine—Tension—Formoterol—chronic obstructive pulmonary disease	0.000582	0.00303	CcSEcCtD
Vidarabine—Tension—Arformoterol—chronic obstructive pulmonary disease	0.000582	0.00303	CcSEcCtD
Vidarabine—Dysgeusia—Formoterol—chronic obstructive pulmonary disease	0.00058	0.00302	CcSEcCtD
Vidarabine—Dysgeusia—Arformoterol—chronic obstructive pulmonary disease	0.00058	0.00302	CcSEcCtD
Vidarabine—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000579	0.00302	CcSEcCtD
Vidarabine—Nervousness—Arformoterol—chronic obstructive pulmonary disease	0.000576	0.003	CcSEcCtD
Vidarabine—Nervousness—Formoterol—chronic obstructive pulmonary disease	0.000576	0.003	CcSEcCtD
Vidarabine—Arrhythmia—Salbutamol—chronic obstructive pulmonary disease	0.000574	0.00299	CcSEcCtD
Vidarabine—Back pain—Arformoterol—chronic obstructive pulmonary disease	0.000573	0.00298	CcSEcCtD
Vidarabine—Back pain—Formoterol—chronic obstructive pulmonary disease	0.000573	0.00298	CcSEcCtD
Vidarabine—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000566	0.00295	CcSEcCtD
Vidarabine—Tremor—Formoterol—chronic obstructive pulmonary disease	0.000555	0.00289	CcSEcCtD
Vidarabine—Tremor—Arformoterol—chronic obstructive pulmonary disease	0.000555	0.00289	CcSEcCtD
Vidarabine—Tension—Salbutamol—chronic obstructive pulmonary disease	0.000549	0.00286	CcSEcCtD
Vidarabine—Dysgeusia—Salbutamol—chronic obstructive pulmonary disease	0.000548	0.00285	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.000546	0.00284	CcSEcCtD
Vidarabine—Agitation—Formoterol—chronic obstructive pulmonary disease	0.000545	0.00283	CcSEcCtD
Vidarabine—Agitation—Arformoterol—chronic obstructive pulmonary disease	0.000545	0.00283	CcSEcCtD
Vidarabine—Tremor—Montelukast—chronic obstructive pulmonary disease	0.000544	0.00283	CcSEcCtD
Vidarabine—Nervousness—Salbutamol—chronic obstructive pulmonary disease	0.000544	0.00283	CcSEcCtD
Vidarabine—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.000542	0.00282	CcSEcCtD
Vidarabine—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.000542	0.00282	CcSEcCtD
Vidarabine—Back pain—Salbutamol—chronic obstructive pulmonary disease	0.000541	0.00282	CcSEcCtD
Vidarabine—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	0.000538	0.0028	CcSEcCtD
Vidarabine—Agitation—Montelukast—chronic obstructive pulmonary disease	0.000534	0.00278	CcSEcCtD
Vidarabine—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.00053	0.00276	CcSEcCtD
Vidarabine—Affect lability—Prednisolone—chronic obstructive pulmonary disease	0.000525	0.00273	CcSEcCtD
Vidarabine—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.000524	0.00273	CcSEcCtD
Vidarabine—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.000524	0.00273	CcSEcCtD
Vidarabine—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.000524	0.00273	CcSEcCtD
Vidarabine—Cough—Formoterol—chronic obstructive pulmonary disease	0.000517	0.00269	CcSEcCtD
Vidarabine—Cough—Arformoterol—chronic obstructive pulmonary disease	0.000517	0.00269	CcSEcCtD
Vidarabine—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.000514	0.00268	CcSEcCtD
Vidarabine—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.000513	0.00267	CcSEcCtD
Vidarabine—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.000512	0.00266	CcSEcCtD
Vidarabine—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.000512	0.00266	CcSEcCtD
Vidarabine—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.000511	0.00266	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—GSTM1—chronic obstructive pulmonary disease	0.000507	0.0207	CbGpPWpGaD
Vidarabine—Cardiac arrest—Prednisolone—chronic obstructive pulmonary disease	0.000507	0.00264	CcSEcCtD
Vidarabine—Cough—Montelukast—chronic obstructive pulmonary disease	0.000507	0.00264	CcSEcCtD
Vidarabine—Mood swings—Prednisolone—chronic obstructive pulmonary disease	0.000505	0.00263	CcSEcCtD
Vidarabine—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000505	0.00263	CcSEcCtD
Vidarabine—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.000505	0.00263	CcSEcCtD
Vidarabine—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.000505	0.00263	CcSEcCtD
Vidarabine—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.000503	0.00262	CcSEcCtD
Vidarabine—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000503	0.00262	CcSEcCtD
Vidarabine—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000503	0.00262	CcSEcCtD
Vidarabine—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000502	0.00261	CcSEcCtD
Vidarabine—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.000499	0.00259	CcSEcCtD
Vidarabine—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000499	0.00259	CcSEcCtD
Vidarabine—DPP4—Peptide hormone metabolism—LEP—chronic obstructive pulmonary disease	0.000496	0.0203	CbGpPWpGaD
Vidarabine—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000495	0.00257	CcSEcCtD
Vidarabine—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000494	0.00257	CcSEcCtD
Vidarabine—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000494	0.00257	CcSEcCtD
Vidarabine—ADORA2A—GPCRs, Other—CXCR2—chronic obstructive pulmonary disease	0.000493	0.0201	CbGpPWpGaD
Vidarabine—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000493	0.00256	CcSEcCtD
Vidarabine—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000492	0.00256	CcSEcCtD
Vidarabine—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000488	0.00254	CcSEcCtD
Vidarabine—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000484	0.00252	CcSEcCtD
Vidarabine—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000484	0.00252	CcSEcCtD
Vidarabine—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000483	0.00251	CcSEcCtD
Vidarabine—ADORA2A—G alpha (s) signalling events—PDE4A—chronic obstructive pulmonary disease	0.000478	0.0195	CbGpPWpGaD
Vidarabine—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000476	0.00248	CcSEcCtD
Vidarabine—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000476	0.00248	CcSEcCtD
Vidarabine—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000475	0.00247	CcSEcCtD
Vidarabine—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000474	0.00247	CcSEcCtD
Vidarabine—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000472	0.00246	CcSEcCtD
Vidarabine—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000472	0.00246	CcSEcCtD
Vidarabine—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000471	0.00245	CcSEcCtD
Vidarabine—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000468	0.00244	CcSEcCtD
Vidarabine—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000466	0.00243	CcSEcCtD
Vidarabine—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000457	0.00238	CcSEcCtD
Vidarabine—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000452	0.00235	CcSEcCtD
Vidarabine—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000452	0.00235	CcSEcCtD
Vidarabine—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000449	0.00234	CcSEcCtD
Vidarabine—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000446	0.00232	CcSEcCtD
Vidarabine—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000442	0.0023	CcSEcCtD
Vidarabine—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000442	0.0023	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000441	0.00229	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000441	0.00229	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000432	0.00225	CcSEcCtD
Vidarabine—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000431	0.00224	CcSEcCtD
Vidarabine—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000431	0.00224	CcSEcCtD
Vidarabine—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.00043	0.00224	CcSEcCtD
Vidarabine—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.00043	0.00224	CcSEcCtD
Vidarabine—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000427	0.00222	CcSEcCtD
Vidarabine—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000425	0.00221	CcSEcCtD
Vidarabine—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000421	0.00219	CcSEcCtD
Vidarabine—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.00042	0.00219	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000416	0.00217	CcSEcCtD
Vidarabine—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000414	0.00215	CcSEcCtD
Vidarabine—Pain—Formoterol—chronic obstructive pulmonary disease	0.000414	0.00215	CcSEcCtD
Vidarabine—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.00041	0.00213	CcSEcCtD
Vidarabine—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000407	0.00212	CcSEcCtD
Vidarabine—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000406	0.00211	CcSEcCtD
Vidarabine—Pain—Montelukast—chronic obstructive pulmonary disease	0.000405	0.00211	CcSEcCtD
Vidarabine—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000405	0.00211	CcSEcCtD
Vidarabine—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000404	0.0021	CcSEcCtD
Vidarabine—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.000403	0.0021	CcSEcCtD
Vidarabine—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000401	0.00209	CcSEcCtD
Vidarabine—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.0004	0.00208	CcSEcCtD
Vidarabine—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000398	0.00207	CcSEcCtD
Vidarabine—Cardiac failure—Prednisone—chronic obstructive pulmonary disease	0.000397	0.00207	CcSEcCtD
Vidarabine—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000396	0.00206	CcSEcCtD
Vidarabine—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000391	0.00203	CcSEcCtD
Vidarabine—ADORA2A—HIF-2-alpha transcription factor network—SERPINE1—chronic obstructive pulmonary disease	0.000388	0.0158	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—MUC5AC—chronic obstructive pulmonary disease	0.000385	0.0157	CbGpPWpGaD
Vidarabine—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000384	0.002	CcSEcCtD
Vidarabine—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000384	0.002	CcSEcCtD
Vidarabine—Affect lability—Prednisone—chronic obstructive pulmonary disease	0.000381	0.00198	CcSEcCtD
Vidarabine—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000381	0.00198	CcSEcCtD
Vidarabine—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000378	0.00197	CcSEcCtD
Vidarabine—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000378	0.00196	CcSEcCtD
Vidarabine—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000378	0.00196	CcSEcCtD
Vidarabine—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000376	0.00196	CcSEcCtD
Vidarabine—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000376	0.00195	CcSEcCtD
Vidarabine—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.000375	0.00195	CcSEcCtD
Vidarabine—Cardiac arrest—Prednisone—chronic obstructive pulmonary disease	0.000368	0.00192	CcSEcCtD
Vidarabine—Mood swings—Prednisone—chronic obstructive pulmonary disease	0.000367	0.00191	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—SLC6A4—chronic obstructive pulmonary disease	0.000364	0.0149	CbGpPWpGaD
Vidarabine—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000363	0.00189	CcSEcCtD
Vidarabine—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000356	0.00185	CcSEcCtD
Vidarabine—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000356	0.00185	CcSEcCtD
Vidarabine—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000356	0.00185	CcSEcCtD
Vidarabine—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000349	0.00182	CcSEcCtD
Vidarabine—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000347	0.00181	CcSEcCtD
Vidarabine—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000347	0.00181	CcSEcCtD
Vidarabine—ADA—p73 transcription factor network—SERPINE1—chronic obstructive pulmonary disease	0.000344	0.0141	CbGpPWpGaD
Vidarabine—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.00034	0.00177	CcSEcCtD
Vidarabine—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000337	0.00175	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—ADIPOQ—chronic obstructive pulmonary disease	0.000334	0.0137	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—HDAC2—chronic obstructive pulmonary disease	0.000333	0.0136	CbGpPWpGaD
Vidarabine—ADORA2A—Monoamine Transport—IL1B—chronic obstructive pulmonary disease	0.000331	0.0135	CbGpPWpGaD
Vidarabine—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000329	0.00171	CcSEcCtD
Vidarabine—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000328	0.00171	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—MUC1—chronic obstructive pulmonary disease	0.000327	0.0134	CbGpPWpGaD
Vidarabine—ADK—Metabolism—APIP—chronic obstructive pulmonary disease	0.000321	0.0131	CbGpPWpGaD
Vidarabine—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.00032	0.00166	CcSEcCtD
Vidarabine—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.00032	0.00166	CcSEcCtD
Vidarabine—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000313	0.00163	CcSEcCtD
Vidarabine—ADORA2A—GPCRs, Other—ADRB2—chronic obstructive pulmonary disease	0.000309	0.0126	CbGpPWpGaD
Vidarabine—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000308	0.0016	CcSEcCtD
Vidarabine—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000308	0.0016	CcSEcCtD
Vidarabine—Rash—Formoterol—chronic obstructive pulmonary disease	0.000305	0.00159	CcSEcCtD
Vidarabine—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000305	0.00159	CcSEcCtD
Vidarabine—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000305	0.00159	CcSEcCtD
Vidarabine—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000305	0.00159	CcSEcCtD
Vidarabine—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000303	0.00158	CcSEcCtD
Vidarabine—Headache—Formoterol—chronic obstructive pulmonary disease	0.000303	0.00158	CcSEcCtD
Vidarabine—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000303	0.00157	CcSEcCtD
Vidarabine—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000302	0.00157	CcSEcCtD
Vidarabine—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000301	0.00157	CcSEcCtD
Vidarabine—Rash—Montelukast—chronic obstructive pulmonary disease	0.000299	0.00155	CcSEcCtD
Vidarabine—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000298	0.00155	CcSEcCtD
Vidarabine—Headache—Montelukast—chronic obstructive pulmonary disease	0.000297	0.00154	CcSEcCtD
Vidarabine—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	0.000294	0.00153	CcSEcCtD
Vidarabine—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000293	0.00153	CcSEcCtD
Vidarabine—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	0.000293	0.00152	CcSEcCtD
Vidarabine—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.00029	0.00151	CcSEcCtD
Vidarabine—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000288	0.0015	CcSEcCtD
Vidarabine—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000288	0.0015	CcSEcCtD
Vidarabine—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000288	0.0015	CcSEcCtD
Vidarabine—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000287	0.0015	CcSEcCtD
Vidarabine—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000287	0.0015	CcSEcCtD
Vidarabine—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000286	0.00149	CcSEcCtD
Vidarabine—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000282	0.00147	CcSEcCtD
Vidarabine—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000281	0.00146	CcSEcCtD
Vidarabine—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000278	0.00145	CcSEcCtD
Vidarabine—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000277	0.00144	CcSEcCtD
Vidarabine—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.000273	0.00142	CcSEcCtD
Vidarabine—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000271	0.00141	CcSEcCtD
Vidarabine—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.00027	0.00141	CcSEcCtD
Vidarabine—ADORA2A—HIF-2-alpha transcription factor network—VEGFA—chronic obstructive pulmonary disease	0.000267	0.0109	CbGpPWpGaD
Vidarabine—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000262	0.00136	CcSEcCtD
Vidarabine—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000258	0.00134	CcSEcCtD
Vidarabine—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000256	0.00133	CcSEcCtD
Vidarabine—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000253	0.00132	CcSEcCtD
Vidarabine—Flushing—Prednisone—chronic obstructive pulmonary disease	0.000249	0.00129	CcSEcCtD
Vidarabine—ADORA2A—GPCRs, Other—HTR2A—chronic obstructive pulmonary disease	0.000242	0.00988	CbGpPWpGaD
Vidarabine—ADORA2A—G alpha (s) signalling events—ADRB2—chronic obstructive pulmonary disease	0.000242	0.00987	CbGpPWpGaD
Vidarabine—ADORA2A—Monoamine Transport—TNF—chronic obstructive pulmonary disease	0.00024	0.0098	CbGpPWpGaD
Vidarabine—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.000239	0.00125	CcSEcCtD
Vidarabine—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000235	0.00122	CcSEcCtD
Vidarabine—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000224	0.00117	CcSEcCtD
Vidarabine—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.00022	0.00114	CcSEcCtD
Vidarabine—ADA—Metabolism—APIP—chronic obstructive pulmonary disease	0.000218	0.00891	CbGpPWpGaD
Vidarabine—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000214	0.00112	CcSEcCtD
Vidarabine—ADORA2A—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.000214	0.00875	CbGpPWpGaD
Vidarabine—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000213	0.00111	CcSEcCtD
Vidarabine—ADK—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	0.000213	0.00868	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—SLC6A4—chronic obstructive pulmonary disease	0.000209	0.00854	CbGpPWpGaD
Vidarabine—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000209	0.00109	CcSEcCtD
Vidarabine—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000208	0.00108	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—LEP—chronic obstructive pulmonary disease	0.000208	0.00848	CbGpPWpGaD
Vidarabine—ADK—Metabolism—GC—chronic obstructive pulmonary disease	0.000207	0.00844	CbGpPWpGaD
Vidarabine—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000205	0.00107	CcSEcCtD
Vidarabine—Convulsion—Prednisone—chronic obstructive pulmonary disease	0.000202	0.00105	CcSEcCtD
Vidarabine—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000201	0.00105	CcSEcCtD
Vidarabine—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000198	0.00103	CcSEcCtD
Vidarabine—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000196	0.00102	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—NOS2—chronic obstructive pulmonary disease	0.000194	0.00791	CbGpPWpGaD
Vidarabine—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000193	0.001	CcSEcCtD
Vidarabine—ADK—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	0.000192	0.00785	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—ADIPOQ—chronic obstructive pulmonary disease	0.000192	0.00784	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—HDAC2—chronic obstructive pulmonary disease	0.000191	0.00781	CbGpPWpGaD
Vidarabine—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.00019	0.000991	CcSEcCtD
Vidarabine—Shock—Prednisone—chronic obstructive pulmonary disease	0.000187	0.000975	CcSEcCtD
Vidarabine—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.000186	0.000967	CcSEcCtD
Vidarabine—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000184	0.000958	CcSEcCtD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000184	0.0075	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—KL—chronic obstructive pulmonary disease	0.000174	0.00712	CbGpPWpGaD
Vidarabine—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000173	0.000903	CcSEcCtD
Vidarabine—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000173	0.000902	CcSEcCtD
Vidarabine—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	0.000171	0.00089	CcSEcCtD
Vidarabine—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000165	0.00086	CcSEcCtD
Vidarabine—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000165	0.000859	CcSEcCtD
Vidarabine—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000164	0.000854	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—SERPINE1—chronic obstructive pulmonary disease	0.000163	0.00666	CbGpPWpGaD
Vidarabine—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000156	0.00081	CcSEcCtD
Vidarabine—Urticaria—Prednisone—chronic obstructive pulmonary disease	0.000151	0.000787	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—ACE—chronic obstructive pulmonary disease	0.000151	0.00616	CbGpPWpGaD
Vidarabine—ADA—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	0.000144	0.0059	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—HDAC2—chronic obstructive pulmonary disease	0.000144	0.00589	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GC—chronic obstructive pulmonary disease	0.000141	0.00574	CbGpPWpGaD
Vidarabine—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.00014	0.00073	CcSEcCtD
Vidarabine—ADORA2A—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.00014	0.00571	CbGpPWpGaD
Vidarabine—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000137	0.000711	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—PLAUR—chronic obstructive pulmonary disease	0.000135	0.00553	CbGpPWpGaD
Vidarabine—ADORA2A—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000134	0.00549	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—KL—chronic obstructive pulmonary disease	0.000134	0.00548	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—ERBB3—chronic obstructive pulmonary disease	0.000131	0.00534	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	0.000131	0.00534	CbGpPWpGaD
Vidarabine—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000126	0.000655	CcSEcCtD
Vidarabine—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000121	0.00063	CcSEcCtD
Vidarabine—Rash—Prednisone—chronic obstructive pulmonary disease	0.00012	0.000625	CcSEcCtD
Vidarabine—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.00012	0.000624	CcSEcCtD
Vidarabine—ADORA2A—Circadian rythm related genes—LEP—chronic obstructive pulmonary disease	0.000119	0.00487	CbGpPWpGaD
Vidarabine—Headache—Prednisone—chronic obstructive pulmonary disease	0.000119	0.000621	CcSEcCtD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000115	0.0047	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000115	0.00468	CbGpPWpGaD
Vidarabine—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000113	0.000588	CcSEcCtD
Vidarabine—ADK—Metabolism—GSTT1—chronic obstructive pulmonary disease	0.000113	0.00461	CbGpPWpGaD
Vidarabine—ADK—Metabolism—GCLC—chronic obstructive pulmonary disease	0.000112	0.00456	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—NOS2—chronic obstructive pulmonary disease	0.000111	0.00454	CbGpPWpGaD
Vidarabine—ADORA2A—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000105	0.00429	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000103	0.0042	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CTGF—chronic obstructive pulmonary disease	0.000102	0.00416	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—ERBB3—chronic obstructive pulmonary disease	0.000101	0.00411	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	9.8e-05	0.004	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—MMP1—chronic obstructive pulmonary disease	9.68e-05	0.00395	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CYP1A2—chronic obstructive pulmonary disease	9.39e-05	0.00383	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—LEP—chronic obstructive pulmonary disease	9.36e-05	0.00382	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—SERPINE1—chronic obstructive pulmonary disease	9.36e-05	0.00382	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	9e-05	0.00368	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	8.9e-05	0.00364	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	8.77e-05	0.00358	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	8.47e-05	0.00346	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	7.9e-05	0.00323	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	7.84e-05	0.0032	CbGpPWpGaD
Vidarabine—ADK—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.83e-05	0.0032	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	7.75e-05	0.00317	CbGpPWpGaD
Vidarabine—ADK—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.72e-05	0.00315	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.68e-05	0.00314	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GCLC—chronic obstructive pulmonary disease	7.59e-05	0.0031	CbGpPWpGaD
Vidarabine—ADK—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.2e-05	0.00294	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	7.18e-05	0.00293	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	6.94e-05	0.00283	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CTGF—chronic obstructive pulmonary disease	6.93e-05	0.00283	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	6.86e-05	0.0028	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.82e-05	0.00279	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.38e-05	0.00261	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—CXCL8—chronic obstructive pulmonary disease	6.22e-05	0.00254	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—EGFR—chronic obstructive pulmonary disease	5.68e-05	0.00232	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	5.56e-05	0.00227	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.32e-05	0.00217	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	5.26e-05	0.00215	CbGpPWpGaD
Vidarabine—ADA—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.25e-05	0.00214	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	4.96e-05	0.00202	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.89e-05	0.002	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	4.87e-05	0.00199	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.64e-05	0.00189	CbGpPWpGaD
Vidarabine—ADK—Metabolism—ALB—chronic obstructive pulmonary disease	4.64e-05	0.00189	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	4.5e-05	0.00184	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	4.45e-05	0.00182	CbGpPWpGaD
Vidarabine—ADK—Metabolism—NOS3—chronic obstructive pulmonary disease	4.43e-05	0.00181	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	4.43e-05	0.00181	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—EGFR—chronic obstructive pulmonary disease	4.37e-05	0.00178	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6—chronic obstructive pulmonary disease	4.37e-05	0.00178	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	4.24e-05	0.00173	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	4.24e-05	0.00173	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	4.02e-05	0.00164	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	3.88e-05	0.00158	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	3.52e-05	0.00144	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—IL6—chronic obstructive pulmonary disease	3.36e-05	0.00137	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ALB—chronic obstructive pulmonary disease	3.15e-05	0.00129	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	3.1e-05	0.00127	CbGpPWpGaD
Vidarabine—ADA—Metabolism—NOS3—chronic obstructive pulmonary disease	3.01e-05	0.00123	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.88e-05	0.00118	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	2.66e-05	0.00109	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	2.39e-05	0.000978	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	2.38e-05	0.00097	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	2.17e-05	0.000888	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	2.16e-05	0.000882	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	2.08e-05	0.000849	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.93e-05	0.000789	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.59e-05	0.000649	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.52e-05	0.000619	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.45e-05	0.000591	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.28e-05	0.000524	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	1.22e-05	0.000499	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.16e-05	0.000474	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.04e-05	0.000426	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	9.57e-06	0.000391	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	9.39e-06	0.000383	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	7.88e-06	0.000322	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	7.21e-06	0.000295	CbGpPWpGaD
